ELI Lilly is spending another US$3 billion to build out its US manufacturing footprint as it ramps up production of its ...
Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines. The drugmaker said the Kenosha County, ...
On Wednesday, Lilly said a head-to-head study showed participants who took Zepbound lost significantly more weight on average ...
More than 40 percent of Americans are now classified as obese while 75 percent of adults are either overweight or obese. A new group of drugs called GLP-1 receptor agonists have come on the scene to ...
Eli Lilly said it would invest $3 billion to expand a recently acquired manufacturing facility to meet growing demand for its diabetes and weight-loss medicines.
(Reuters) - Eli Lilly said on Thursday it will invest $3 billion to expand the manufacturing plant it bought in Pleasant ...
Lilly’s blockbuster weight-loss and diabetes drugs have made it the most valuable pharmaceutical company in the world.
STAT reporters Helen Branswell and Allison DeAngelis give updates, respectively, on bird flu and radiopharmaceuticals.
These days, with its revenue booming and a market cap swelling to twice the size of | Eli Lilly said it will spend $3 billion ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...
Some people are taking tiny amounts of weight loss medications, hoping to drop pounds while avoiding side effects. Does it ...
Glucagon-like peptide-1 (GLP-1) brands Wegovy and Zepbound, along with their counterparts approved for type 2 diabetes — Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, respectively — have begun to ...